Ian Read

Pfizer Beats Estimates on Strength in Key Drugs
Financial Performance

Pfizer Beats Estimates on Strength in Key Drugs

Sales from Pfizer's innovative health division were particularly strong in the second quarter, with anti-smoking drug Chantix up 8% to $8.2 billion.
By Matthew Heller | July 31, 2018
Read More
Generic Competition Hits Pfizer’s Q2 Sales
Financial Performance

Generic Competition Hits Pfizer’s Q2 Sales

The drug maker cites headwinds from losses of market exclusivity for the 14% drop in Essential Health revenues.
By Matthew Heller | August 2, 2017
Read More